Study of the Application of CAR-T Cell Therapy in Acute Lymphocytic Leukemia

Abstract

Currently, the acute lymphocytic leukemia (ALL), which is a severe blood cancer that mostly found in children, can applied with the most updated CAR-T cell therapy for the cure. ALL incidence rate is around fifteen in one hundred thousand people, which is just lower than the incidence rate of Chronic Lymphocytic Leukemia. And the ALL occupied one-fifth of the leukemia cases. With the application of CAR-T cell therapy, ALL can be cured with higher long-term survival rate. But the CAR-T cell therapy brings some negative impact towards patient body like Cytokine Release Syndrome (CRS). The limitations and adverse actions of the therapy needs to be overcome or minimized to achieve the best prospect of treating patients. In this paper, the first part will briefly introduce present situations of ALL and the CAR-T cell therapy, and the following parts will explain mechanism of CAR-T cell therapy, limitations of the therapy on this disease, and future development of the therapy.